When compared to surgical biopsy, acquiring a cytology specimen is minimally invasive, requiring only a brush sample of epithelial cells. The test helps differentiate benign oral lesions from potentially malignant ones. This ground-breaking test is based on measurement of large-scale DNA abnormalities from cytology preparations using Health Canada approved image cytometry technology. For more information, visit www.secondsteplabs.com.
About PMI Labs
PMI Labs is the laboratory services segment of Perceptronix Medical Inc. accredited with the Diagnostic Accreditation Program of BC Physicians and Surgeons. Founded in 1999, Perceptronix Medical Inc is an ISO 9001:2000 and ISO 13485:2003 certified company providing anatomic pathology services to medical and dental professionals in support of earlier diagnosis for better patient outcomes.
PMI Labs has developed a proprietary quantitative cytology technology to provide new, highly informative early cancer detection tests. The technology was developed in partnership with the British Columbia Cancer Agency (Cancer Research Center) in Vancouver, a renowned cancer research and treatment facility with a successful track record in implementing early cancer detection programs. For more information, visit www.pmilabs.com.
About LED Medical Diagnostics Inc.
Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED-based visualization technologies for the medical industry. The Company is currently listed on the Toronto Stock Exchange (TSX-V) under the symbol "LMD", the OTCQX under the symbol "LEDIF", as well as the Frankfurt Stock Exchange under the symbol "LME". For more information, visit www.ledmd.com.
Through its wholly-owned subsidiary, LED Dental Inc., the company manufactures the VELscope® Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. VELscope® Vx devices are now used to conduct more screenings for oral cancer and other oral tissue abnormalities than any other adjunctive device. For more information, visit www.leddental.com.
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking information includes statements regarding the potential expansion of the Company's technology to other medical applications. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to, product development risks such as regulatory, design, intellectual property, technological and competitor risk and the risk factors described in the Company's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2011. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Add to Digg Bookmark with del.icio.us Add to Newsvine
LED Medical Diagnostics Inc.
Mark Komonoski, Investor Relations
(403) 255-8483 or Toll-Free: (877) 255-8483
Cell: (403) 470-8384
Most Popular Stories
- Twitter Coming to Phones Without Internet
- Twitter Names Woman to Board
- Rand Paul Signs up for Obamacare
- Thalia Gets Star on Hollywood Walk of Fame
- How to Arm Yourself Against CryptoLocker Virus
- Obamacare Doing Just Fine, Ky. Governor Says
- Warner Bros. Unleashes 'Hobbit: Desolation of Smaug' Merchandise
- World Cup Draws: Coaches, Players Offer Insights
- Texas Chiller Moves East
- Hispanic Employment Improves in November